Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
0(0%)
Results Posted
50%(3 trials)

Phase Distribution

Ph phase_3
2
22%
Ph phase_4
1
11%
Ph not_applicable
5
56%
Ph early_phase_1
1
11%

Phase Distribution

1

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution9 total trials
Early Phase 1First-in-human
1(11.1%)
Phase 3Large-scale testing
2(22.2%)
Phase 4Post-market surveillance
1(11.1%)
N/ANon-phased studies
5(55.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(6)
Other(3)

Detailed Status

Completed6
unknown3

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (11.1%)
Phase 32 (22.2%)
Phase 41 (11.1%)
N/A5 (55.6%)

Trials by Status

completed667%
unknown333%

Recent Activity

0 active trials
Showing 5 of 9
completednot_applicable

Acetylcholine, Tobacco Smoking, Genes and Nicotinic Receptors

NCT02008292
completedphase_4

Treatment of Adolescent Antimuscarinic (Anticholinergic) Toxidrome

NCT03090620
completednot_applicable

Anticholium® Per Se

NCT03013322
unknownphase_3

Evaluation if Physostigmine Reduces Symptoms in Patients Who Has Developed a Delirium in Intensive Care After a Surgery

NCT02216266
completednot_applicable

Phamacological Reversal of Airway Instability During Sedation

NCT01171118
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT02008292Not Applicable

Acetylcholine, Tobacco Smoking, Genes and Nicotinic Receptors

Completed
NCT03090620Phase 4

Treatment of Adolescent Antimuscarinic (Anticholinergic) Toxidrome

Completed
NCT03013322Not Applicable

Anticholium® Per Se

Completed
NCT02216266Phase 3

Evaluation if Physostigmine Reduces Symptoms in Patients Who Has Developed a Delirium in Intensive Care After a Surgery

Unknown
NCT01171118Not Applicable

Phamacological Reversal of Airway Instability During Sedation

Completed
NCT01394445Phase 3

Pilot Study of Physostigmine-Enhanced Opioid Analgesia

Completed
NCT00850850Not Applicable

Physostigmine After General Anesthesia

Unknown
NCT01121497Not Applicable

The Effect of Physostigmine on Cognitive Functioning in the Immediate Period After Sedation for Colonoscopy

Unknown
NCT00689208Early Phase 1

Pharmacological Intervention in Insulin Resistance Targeting Autonomic Nerve Activity

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9